These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 33089790)

  • 1. Immune-mediated necrotising myopathy is a rare statin-associated adverse effect: a case report.
    Lee KF; Mak MWH; Lao VWN; Yip HLK; Lau WY; Wong VTL
    Hong Kong Med J; 2020 Oct; 26(5):441-443. PubMed ID: 33089790
    [No Abstract]   [Full Text] [Related]  

  • 2. Atorvastatin-induced gynecomastia in a dyslipidemic patient: A case report.
    Bostanitis I; Tsalidou M
    Hellenic J Cardiol; 2019; 60(3):194-195. PubMed ID: 30145234
    [No Abstract]   [Full Text] [Related]  

  • 3. Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study.
    Kaasenbrood L; Poulter NR; Sever PS; Colhoun HM; Livingstone SJ; Boekholdt SM; Pressel SL; Davis BR; van der Graaf Y; Visseren FL;
    Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):213-21. PubMed ID: 27174798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
    Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
    Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase.
    Essers D; Schäublin M; Kullak-Ublick GA; Weiler S
    Eur J Clin Pharmacol; 2019 Mar; 75(3):409-416. PubMed ID: 30430215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol efflux capacity of large, small and total HDL particles is unaltered by atorvastatin in patients with type 2 diabetes.
    Muñoz-Hernandez L; Ortiz-Bautista RJ; Brito-Córdova G; Lozano-Arvizu F; Saucedo S; Pérez-Méndez O; Zentella-Dehesa A; Dauteuille C; Lhomme M; Lesnik P; Chapman MJ; Kontush A; Aguilar Salinas CA
    Atherosclerosis; 2018 Oct; 277():72-79. PubMed ID: 30176567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.
    Le NA; Tomassini JE; Tershakovec AM; Neff DR; Wilson PW
    J Am Heart Assoc; 2015 Oct; 4(10):e001675. PubMed ID: 26486166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.
    Verma S; Leiter LA; Mazer CD; Bain SC; Buse J; Marso S; Nauck M; Zinman B; Bosch-Traberg H; Rasmussen S; Michelsen MM; Bhatt DL
    Circulation; 2018 Oct; 138(15):1605-1607. PubMed ID: 30354517
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of fenofibrate in clinical practice.
    Zambon A; Cusi K
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of 12-month intervention with low-dose atorvastatin on pulse wave velocity in subjects with type 2 diabetes and dyslipidaemia.
    Grigoropoulou P; Tentolouris A; Eleftheriadou I; Tsilingiris D; Vlachopoulos C; Sykara M; Tentolouris N
    Diab Vasc Dis Res; 2019 Jan; 16(1):38-46. PubMed ID: 30328360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations of plant sterols, lathosterol, oxidative stress and inflammatory markers after the combination therapy of ezetimibe and statin drugs in type 2 diabetic patients.
    Naruse R; Hori K; Terasawa T; Hara K; Suetsugu M; Takebayashi K; Morita K; Aso Y; Inukai T
    Obes Res Clin Pract; 2015; 9(1):67-74. PubMed ID: 25660177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of atorvastatin on baroreflex sensitivity in subjects with type 2 diabetes and dyslipidaemia.
    Grigoropoulou P; Eleftheriadou I; Zoupas C; Makrilakis K; Papassotiriou I; Margeli A; Perrea D; Katsilambros N; Tentolouris N
    Diab Vasc Dis Res; 2014 Jan; 11(1):26-33. PubMed ID: 24154932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of atorvastatin versus rosuvastatin on inflammatory biomarkers and LV function in type 2 diabetic patients with dyslipidemia.
    Werida R; Khairat I; Khedr NF
    Biomed Pharmacother; 2021 Mar; 135():111179. PubMed ID: 33401219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Titration to High-Intensity Statin Therapy Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus.
    Giustino G; Colantonio LD; Brown TM; Carson AP; Dai Y; Farkouh ME; Monda KL; Muntner P; Rosenson RS
    Cardiovasc Drugs Ther; 2018 Oct; 32(5):453-461. PubMed ID: 30078077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin-associated muscle symptoms in coronary patients: design of a randomized study.
    Munkhaugen J; Vethe NT; Fagerland MW; Dammen T; Perk J; Gjertsen E; Otterstad JE; Gullestad L; Bergan S; Husebye E
    Scand Cardiovasc J; 2019 Jun; 53(3):162-168. PubMed ID: 31030568
    [No Abstract]   [Full Text] [Related]  

  • 16. [Toxic myopathy associated with concomitant treatment with atorvastatin and colchicine].
    Sanchez-Tejerina San Jose D; Ostos-Moliz F; Toldos-Gonzalez O; Gonzalo-Martinez JF; Herrero-San Martin A
    Rev Neurol; 2019 Jun; 68(11):488-489. PubMed ID: 31132138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.
    Nicholls SJ; Ray KK; Ballantyne CM; Beacham LA; Miller DL; Ruotolo G; Nissen SE; Riesmeyer JS;
    Atherosclerosis; 2017 Jun; 261():12-18. PubMed ID: 28412650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Tolerability of Pitavastatin Therapy: A Case Report of Comparison with other Statins.
    Christou GA; Mprikos SG; Christou KA; Christou MA; Christou EA; Nikas DN; Kiortsis DN
    Cardiology; 2020; 145(7):421-424. PubMed ID: 32160627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addressing key questions with statin therapy.
    Toth PP
    J Fam Pract; 2012 Jun; 61(6 Suppl):S34-9. PubMed ID: 22670245
    [No Abstract]   [Full Text] [Related]  

  • 20. Statin potency associated with incident diabetes in a real-world evaluation.
    Steen DL; Bhatt DL
    Evid Based Med; 2014 Apr; 19(2):68. PubMed ID: 23990528
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.